Atlas Trials

Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer

Clinical trial NCT01810913 · SUSPENDED

Trial details

NCT number
NCT01810913
Sponsor
National Cancer Institute (NCI)
Status
SUSPENDED
Phase
Phase 2, Phase 3
Study type
INTERVENTIONAL
Oropharyngeal p16INK4a-Negative Squamous Cell CarcinomaStage III Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage III Laryngeal Squamous Cell Carcinoma AJCC v6 and v7Stage III Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage III Oropharyngeal Squamous Cell Carcinoma AJCC v7Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7Stage IV Laryngeal Squamous Cell Carcinoma AJCC v7Stage IV Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7Stage IV Oropharyngeal Squamous Cell Carcinoma AJCC v7
Start date
2013-03-22
Primary completion
2027-01-01
Enrollment
613

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.